Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03746782 · ClinicalTrials.gov registry record
Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation
A clinical trial of Acute Coronary Syndrome, sponsored by CirQuest Labs.
- Completed
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT03746782: Completed study of Acute Coronary Syndrome, sponsored by CirQuest Labs.
NCT03746782 is a study of Acute Coronary Syndrome that has completed, run by CirQuest Labs. The registered enrollment target is 40 participants, below the 2,721-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03746782, a study of Acute Coronary Syndrome, has completed, sponsored by CirQuest Labs.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigating Synergistic Effects of Apixaban with Dual Anti-Platelet Therapy (DAPT) in Lowering Platelet Reactivity and Thrombin Generation
Primary Outcome
Synergistic effects of in-vitro apixaban with antiplatelet agents in inhibiting platelet reactivity and thrombin generation
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Flow Cytrometry; Thrombin Generation Assay
Study Locations (1)
Tennessee
- CirQuest Labs, LLC - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-07-10 |
| Est. Completion | 2019-11-08 |
What the finished NCT03746782 record still lists
NCT03746782 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 2,721-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Flow Cytrometry; Thrombin Generation Assay is the first listed.
NCT03746782 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT03746782 about?
NCT03746782 is a clinical study titled "Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation". Investigating Synergistic Effects of Apixaban with Dual Anti-Platelet Therapy (DAPT) in Lowering Platelet Reactivity and Thrombin Generation
What is the current status of trial NCT03746782?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2018-07-10. Estimated completion is 2019-11-08.
What conditions does trial NCT03746782 study?
This clinical trial studies the following conditions: Acute Coronary Syndrome.
What interventions are being tested in trial NCT03746782?
The interventions under investigation include: Flow Cytrometry; Thrombin Generation Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03746782?
This trial is sponsored by CirQuest Labs, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03746782 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Coronary Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03746782's enrollment target sits among peer trials
40 38th of 40 higher than 3 of 40 other Acute Coronary Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Coronary Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Polypill for Acute Coronary Syndrome
RECRUITING · Phase 2
-
Positive Emotions Following Acute Cardiac Events
RECRUITING · NA
-
Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane Oxygenation Support During Cardiogenic Shock
RECRUITING
-
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
RECRUITING · Phase 3
-
A Prospective Research Investigation of Ischemia Using MCG
RECRUITING
-
AngelMed Guardian® System PMA Post Approval Study
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI